PMID- 32199749
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20201214
IS  - 1878-1594 (Electronic)
IS  - 1521-690X (Linking)
VI  - 34
IP  - 4
DP  - 2020 Jul
TI  - Management of thyrotoxicosis during pregnancy.
PG  - 101414
LID - S1521-690X(20)30041-5 [pii]
LID - 10.1016/j.beem.2020.101414 [doi]
AB  - Thyrotoxicosis during pregnancy should be adequately managed and controlled to 
      prevent maternal and fetal complications. The evaluation of thyroid function in 
      pregnant women is challenged by the physiological adaptations associated with 
      pregnancy, and the treatment with antithyroid drugs (ATD) raises concerns for the 
      pregnant woman and the fetus. Thyrotoxicosis in pregnant women is mainly of 
      autoimmune origin, and the measurement of thyroid stimulating hormone-receptor 
      antibodies (TRAb) plays a key role. TRAb helps to distinguish the hyperthyroidism 
      of Graves' disease from gestational hyperthyroidism in early pregnancy, and to 
      evaluate the risk of fetal and neonatal hyperthyroidism in late pregnancy. 
      Furthermore, the measurement of TRAb in early pregnancy is recommended to 
      evaluate the need for ATD during the teratogenic period of pregnancy. 
      Observational studies have raised concern about the risk of birth defects 
      associated with the use of ATD in early pregnancy and challenged the clinical 
      management and choice of treatment.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Andersen, Stine Linding
AU  - Andersen SL
AD  - Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, 
      Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 
      Electronic address: stine.a@rn.dk.
FAU - Knosgaard, Louise
AU  - Knosgaard L
AD  - Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, 
      Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200305
PL  - Netherlands
TA  - Best Pract Res Clin Endocrinol Metab
JT  - Best practice & research. Clinical endocrinology & metabolism
JID - 101120682
RN  - 0 (Antithyroid Agents)
RN  - 0 (Immunoglobulins, Thyroid-Stimulating)
RN  - 0 (thyrotropin-binding inhibitory immunoglobulin)
SB  - IM
MH  - Antithyroid Agents/administration & dosage/adverse effects
MH  - Female
MH  - Fetal Diseases/chemically induced/epidemiology/immunology
MH  - Graves Disease/blood/drug therapy/epidemiology
MH  - Humans
MH  - Hyperthyroidism/blood/drug therapy/epidemiology
MH  - Immunoglobulins, Thyroid-Stimulating/analysis/blood
MH  - Infant, Newborn
MH  - Infant, Newborn, Diseases/chemically induced/epidemiology/immunology
MH  - Pregnancy
MH  - Pregnancy Complications/blood/drug therapy/epidemiology/*therapy
MH  - Pregnancy Outcome/epidemiology
MH  - Prenatal Exposure Delayed Effects/chemically induced/epidemiology/immunology
MH  - Thyrotoxicosis/blood/complications/drug therapy/*therapy
OTO - NOTNLM
OT  - TRAb
OT  - antithyroid drugs
OT  - hyperthyroidism
OT  - methimazole
OT  - propylthiouracil
COIS- Declaration of Competing Interest The authors declare that they have no conflict 
      of interests.
EDAT- 2020/03/23 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/03/23 06:00
PHST- 2020/03/23 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/03/23 06:00 [entrez]
AID - S1521-690X(20)30041-5 [pii]
AID - 10.1016/j.beem.2020.101414 [doi]
PST - ppublish
SO  - Best Pract Res Clin Endocrinol Metab. 2020 Jul;34(4):101414. doi: 
      10.1016/j.beem.2020.101414. Epub 2020 Mar 5.